IntelGenx Technologies Corp.

Good day, everyone, and welcome to today's Intel GenX second quarter 2022 financial results call. At this time, all participants are in a listen-only mode. Later, you will have an opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing the star and one on your touchtone phone. I will be standing by if you should need any assistance. And it is now my pleasure to turn today's program over to Stephen Kilmer, Investor Relations.

Thank you. Good afternoon, everyone, and thank you for joining us on today's call. With me on the line are Dr. Horst Hervé, Intelligent Excellence CEO, André Godin, our President and CFO, Dr. Dana Mattson, the company's Vice President of Business and Corporate Development, and Tommy Kenney, our VP, Legal Affairs and Intellectual Property and General Counsel. Before we begin, I would like to remind you that all amounts mentioned today or in U.S. dollars unless otherwise mentioned, and today's call may contain forward-looking information that represents our expectations as of today and accordingly are subject to change. We do not undertake any obligation to update any forward-looking statements except as may be required by U.S. and Canadian securities laws. A number of assumptions were made by us in preparing these forward-looking statements, which are subject to risks and results may differ materially. Details on these risks and assumptions can be found in our filings with the U.S. and Canadian Securities Commission. I'd now like to turn the call over to Dr. Gervais. Horst?

Thank you, Steve. Good afternoon, everyone, and thank you for joining us for the Intergenic second quarter 2022 conference call. On today's call, I will provide a corporate update and discuss the progress we've made on our key pipeline projects. Then André will review our second quarter 2022 financial results, Following that, we will open up the line for our questions. Although we continue to progress each of our development programs during the second quarter, today's corporate update will be brief. Our material use flow, which we expect will be heavier as we enter the four months, was relatively light this quarter. Let me begin with our tie-in. We completed the manufacturing of a clinical trial batch for one of the partner programs. The study materials will be shipped in September, and we anticipate the start of the study later this year, most likely still in the third quarter. Resupport, in May, we met with Exceltis to discuss the potential for the commercialization of Resupport in additional countries. The call was positive, with Exceltis indicating that there is a strong interest for certain Eastern European countries. In addition, We are in discussions with other distribution partners on licensing rights for the MENA region. Moving on to Tadalafil. Intergenics and Equestiv have formed a joint task force to work on the response to the CRM that Equestiv had received for the product. Now moving on to our cannabis films. We are working to fulfill Heritage's purchase order for their resale of our CB4 control film containing CBD to one of the top three licensed producers in Canada. That is expected to happen in early September. Accordingly, we expect the related revenue to be reflected in our Q4 2022 results. Our partner heritage continues to rush CBD distribution in Canada and recently got the product listed on the Shabazz Drug Mart website. We continue to push distribution in Canada and recently met with the Nova Scotia Liquor Corporation to discuss the products. And finally, as to the Tilray litigation, Tommy will be available for questions during the Q&A session. Now moving on to Montelukast, and initially regarding the We're in a study, as we reported earlier in the year, the study and correspondingly our recruitment efforts have resumed. Recruitment is ongoing with six sites activated. As of now, a total of 33 patients have been randomized, 22 of which have completed treatment. We're working diligently to improve the recruitment rate and have now launched a Facebook awareness campaign to attract more study participants and accelerate enrollment. With these currently ongoing activities, we expect to complete enrollment later in Q4 of 2022. Final study results are thus expected to be available in Q2 of 2023. Finally, on animal health, we delivered a beta-film-based clinical trial batch to our undisclosed animal health partner or study in dogs in the U.S. We recently received partial study results and are waiting for the full report to be issued. Once available, we will discuss a tailored program to further develop the product. In addition, we are in discussions with several animal health companies regarding our Betafilm platform. Again, the progress we continue to make is not, at least not fully reflected by this quarter's lighter news flow, which we expect will be a short-term trend. We look forward to updating you on our progress in the coming quarters. And with that, I would now like to turn the call over to Andre for a review of our financial results. Andre?